ICBT, CPRX, EWRC, PRMK, BONU, HLCS OTCPicks.com Stocks to Watch for Tuesday, September 1st

Our Stocks to Watch tomorrow include ICBS Ltd. (OTC: ICBT), Catalyst Pharmaceutical Partners Inc. (Nasdaq: CPRX), eWorld Companies Inc. (OTC: EWRC), ProConcept Marketing Group Inc. (OTC: PRMK), BioNeutral Group Inc. (OTCBB: BONU) and Helicos BioSciences Corp. (Nasdaq: HLCS).

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

ICBS LIMITED (OTC: ICBT)

"Up 366.67% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/ICBT.php 

ICBS Limited operates as a business development, financial and management consulting company in Canada. The company has acquired a 35% percent interest in Pharmicor Inc. a Quebec based pharmaceutical development company. Pharmicor has developed a nasal formula for the treatment of nasal congestions due to allergies and the Rhinovirus. The company acquired Ramapo Valley Brewery NY, Ramapo Valley Brewery Canada Ltd., and Ramapo Valley Brewery. Along with their Gluten free Honey beer, Ramapo Valley Brewery manufactures Copper, Indian Pale Ale, Porter and seasonal beers. The company offers various services, including business consulting, investment banking, incorporation: canadian or provincial, incorporating in the united states, incorporating offshore, business plan, legal council, acquisitions & mergers, turnaround & restructuring, international corporate placement in North America, immigration visas & programs, governments grants, research & development tax credits, accounting systems, bookkeeping services, auditing services, patents, copyrights, trade marks, taxes, budgets, marketing, IPO's public offering in the U.S. and reverse mergers.

ICBT News:

August 28 - BioSpec Global Solutions Inc. Announces Development of Antibody/Antigen Multiple Discrete Optical System for the Simultaneous Analysis of E.coli, Salmonella, Listeria and Pseudomonas in Food Samples

BioSpec Global Solutions Inc. announces development of Antibody/antigen multiple discrete optical system for the simultaneous analysis of E.coli, salmonella, listeria and pseudomonas in food samples

BioSpec Global Solutions Inc. and partner ICBS Ltd. (OTC: ICBT) announced the development of Antibody/antigen multiple discrete optical system (AMUDOS) for the simultaneous analysis of E.coli, salmonella, listeria and pseudomonas in food samples.

The development include the building of hardware and optical system. Software and methodologies for simultaneous detection and enumeration of the above microbes in various types of food samples. TOGS 9000 new model will be a method for the enumeration of total Coliforms, E.coli and Enterococci in fresh water, marine water for routine recreational water testing.

The second phase will be the development and site method validation (for FDA approval) of viable microbial count (VMC or total bacterial count) in water for pharmaceutical quality assurance process.

The Pro3000™ has been verified by Ryerson University, Agriculture Canada and Saskatchewan Department of Health. It has been accepted for use for drinking water analysis by EPA in the USA when used in conjunction with an EPA approved reagent The TOGS 9000 and 3000 have been used in a research project by the World Health Organization in Hawaii and by OCETA in India.

The company holds worldwide patents on the TOGS 3000 and 9000.

CATALYST PHARMACEUTICAL PARTNERS (NASDAQ: CPRX)

"Up 201.78% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/CPRX.php

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.

CPRX News:

August 31 - Catalyst Pharmaceutical Partners Licenses Exclusive Rights to New Class of GABA Aminotransferase Inhibitors From Northwestern University

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced that the Company executed a license agreement under which it acquired exclusive worldwide rights to commercialize novel GABA aminotransferase inhibitors and derivatives of vigabatrin discovered by Northwestern University. These compounds may have applications to a broad range of neurological diseases, including addiction and epilepsy. Catalyst intends to pursue development work on an undisclosed, lead oral compound that has already been identified.

Under the terms of the agreement, Northwestern University granted Catalyst an exclusive worldwide license to certain composition of matter patents related to the new class of inhibitors and a patent application relating to derivatives of vigabatrin. Catalyst will be responsible for the continued research and development of any resulting product candidates. Northwestern University will receive from Catalyst an upfront payment, certain milestone payments relating to clinical development activities, and royalties on products resulting from the agreement. Additional terms of the agreement were not disclosed.

"The agreement with Northwestern University further demonstrates our continuing commitment to developing drugs for the treatment of addiction and obsessive-compulsive disorders and complements our current development platform in several areas," said Patrick McEnany, Chief Executive Officer of Catalyst. "First, this new class of GABA aminotransferase inhibitors is at least 200 times more potent than CPP-109, Catalyst's version of vigabatrin, in in vitro enzyme inhibition kinetics studies. The increased potency could enable the development of superior or alternative dosage forms compared with CPP-109. These compounds may also have superior specificity to GABA aminotransferase and, possibly, a better side effect profile (e.g. less visual field defects) compared to CPP-109. Second, the composition of matter patents for these compounds will ensure exclusivity well beyond the expected exclusivity for CPP-109 and represent an important component in Catalyst's life cycle management of its GABA aminotransferase inhibitor franchise. Based on our reviews of patents and the literature, CPP-109 and these compounds are currently the only ones in development or on the market having GABA aminotransferase inhibition as its primary mode of action. Finally, the new class of compounds will also allow us to explore broader CNS applications that could benefit from the blockade of GABA aminotransferase, including the treatment of epilepsy."

Dr. Richard B. Silverman, the John Evans Professor of Chemistry at Northwestern University, led the team of scientists that invented these compounds. Dr. Silverman holds 41 patents and is the inventor of pregabalin (Lyrica®). He is the recipient of numerous awards, most recently the 2009 Perkin Medal, has published over 250 peer reviewed articles, and has written four books over his 33 year career in academia. Complete details of Dr. Silverman's achievements can be found at http://chemgroups.northwestern.edu/silverman/.

"We are delighted to partner with Catalyst," said Dr. Silverman. "This is another great example of the ability of Northwestern scientists to make exciting discoveries with potential commercial therapeutic applications and to partner with innovative companies such as Catalyst."

ABOUT NORTHWESTERN UNIVERSITY

Founded in 1851, Northwestern University is a leading private research and teaching university with an enrollment of approximately 8,000 full-time undergraduate students and approximately 7,000 full-time graduate and professional students on campuses in Evanston and Chicago, Illinois. Northwestern combines innovative teaching and pioneering research in a highly collaborative environment that transcends traditional academic boundaries. Northwestern provides students and faculty exceptional opportunities for intellectual, personal and professional growth in a setting enhanced by the richness of Chicago.

EWORLD COMPANIES INCORPORATED (OTC: EWRC)

"Up 53.85% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/EWRC.php 

eWorld Companies, Inc. is an online marketing & advertising technologies company that develops and markets cutting edge technologies using rich media, flash, animation and 3D graphics to help individuals and businesses market and advertise online. eWorld's revenue model consists of seven components: (1) Affiliation Fees, (2) Affiliate Monthly Subscriptions, (3) Affiliate Benefit Subscriptions, (4) Product Sales, (5) Advertising Revenues, (6) Web Development Accounts, and (7) International Licensing Fees.

EWRC News:

August 31 - Famed Music Producer Seven Aurelius Joins eWorld Companies, Inc. Advisory Board

eWorld Companies, Inc. (OTC: EWRC) confirmed that Seven Aurelius has joined the company's Advisory Board and will assist the company in securing and producing musical content for its Boomerang Media Station™. Mr. Aurelius, better known by the single name, Seven, is one of the most prodigious hitmakers in the world today, having produced countless #1 records for some of music world's biggest stars and numerous Grammy Award-winning albums for combined sales in excess of 50 million units worldwide. His records were responsible for over $100 million in Def Jam's billings two years in a row and his accomplishments have been featured on the front page of the Wall Street Journal. After delivering huge hits for the biggest female singers in the world, Rolling Stone Magazine dubbed Seven "The King of Divas" in 2003, and that same year ASCAP awarded him its highest honor, "Pop Songwriter of the Year." Seven's production credits include dozens of best-selling R&B and pop recordings and numerous masterpieces for some of the world's top performers, including Mariah Carey, Janet Jackson, Lenny Kravitz, Alicia Keyes, Mary K. Blige. Lil' Kim, Ja Rule, Diddy and others. Among his most famous productions are chart-busters such as "I'm Real" and "Ain't it Funny" by Jennifer Lopez, "Just for You " by Lionel Richie, and "Foolish" by Ashanti.

eWorld CEO Henning Morales commented, "We are pleased to welcome Seven to our team and look forward to the enormous contributions he will make to our success." Seven added, "I believe the eWorld concept and the Boomerang Media Station™ will play key roles in the future of musical entertainment. eWorld intends to make a large impact on the music industry and I am excited to do my part in helping achieve that goal."

PROCONCEPT MARKETING GROUP INCORPORATED (OTC: PRMK)

"Up 150.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/PRMK.php 

ProConcept Marketing Group, Inc., headquartered in Buford, Georgia, is a publicly traded company engaged in business acceleration, business management, and proprietary marketing strategies to major international corporations engaged in diverse industries. ProConcept manages the marketing and distribution of exclusive products and services globally, while involved in the manufacturing process and ownership of these products by creating compelling solutions to generate demand for its products and services.

PRMK News:

August 31 - ProConcept Marketing Group, Inc. Launches Eveline Cosmetic E-Commerce Website

ProConcept Marketing Group, Inc. (OTC: PRMK) announces it has launched their new website, www.evelineusa.com, a totally interactive experience for beauty consumers from around the world. Eveline Cosmetics is the leading cosmetic company in Poland and has operations in 45 countries. Future plans to have shoppers that can read or post product reviews, directly email their favorites to a friend, and take part in beauty related chat forums.

Premier skincare online at www.evelineusa.com was created to help it’s brand identity, the website and packaging to reflect the prestige and luxury qualities of the company and its services, translating elements into a commercially appealing platform. The website creates an identity that will translate well commercially in a luxury online shopping environment.

Eveline Cosmetics is dedicated to sourcing the world’s leading skincare lines in beauty innovation, delivering products of the highest caliber to our discerning customers. A selection of new lines will be revealed in late 2009. With available information in the market it has been estimated that worldwide annual sales on cosmetics is U.S. $34 billion. The demand for cosmetics is expected to grow at an average of 10 percent annually over the next two years. Sales are projected to exceed $39 billion by 2010 and ProConcept Marketing group will capitalize on a percentage of the sales.

“We are beginning with an established and strong electronic media and ecommerce presence immediately for Eveline,” stated Reid Stone, VP of Sales. “The United States has over 215 million internet users, representing 71% of the population. We intend to offer all of Eveline’s 700 products on our site, for men and women.”

ABOUT EVELINE

Eveline Cosmetics is one of the biggest and fastest developing cosmetics producers in Poland. This brand is more than 25 years old and is sold in over 45 countries worldwide. Eveline offers effective care for a demanding skin, and works on fundamental values: Quality and Innovativeness. Eveline has won the “Oskar Kosmetyki” for the past several years in a row, which is the highest award for best cosmetics in Europe.

BIONEUTRAL GROUP INCORPORATED (OTCBB: BONU)

"Up 81.76% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/BONU.php

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene and Ogiene, which are eco-friendly and include natural and common ingredients found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications.

BONU News:

August 31 - BioNeutral and the Chertoff Group Announce a Collaborative Agreement to Continue Development of BioNeutral’s Antimicrobial and Sterilant Technologies

BioNeutral Group, Inc. (OTCBB: BONU) has expanded its relationship with the Chertoff Group (Washington, DC). Beginning September 1, 2009, two senior members of the Chertoff Group will provide dedicated strategic and operational advisory services to BioNeutral to enhance the company’s strategic alliances, corporate operations, product testing, regulatory approvals, capital strategies and sales to the public and private sectors.

“It’s exciting working with the Chertoff Group. We believe their collective talent, combined with BioNeutral's world class chemistry, will make a significant difference in saving lives presently lost to infection. We are proud to combine our efforts to help combat communicable diseases and make the hospital and all health care facilities a safer place,” said Stephen J. Browand, President & CEO of BioNeutral Group.

“As some of the principal architects of homeland security policy and doctrine, our team has a good feel for how to examine problems from end-to-end, and how to evaluate technologies that might be brought to bear in solving those problems,” said former Homeland Secretary Chertoff, Co-Founder and Chairman of the Chertoff Group. “By working with investors, private companies, governments and others who want to grow into homeland security markets, either organically or via acquisitions, I think our firm offers a unique value proposition and perspective. Given our deep knowledge of national and international biosecurity requirements in the commercial and government sectors alike, we are uniquely positioned to help BioNeutral in all aspects of the company’s continuing growth.”

Under terms of the Agreement, Chertoff Group Principal Jeffrey W. Runge, MD and Deputy Chief Operating Officer Dr. J. Bennet Waters will devote approximately half their time exclusively to advising BioNeutral. Dr. Runge will serve as Senior Medical Advisor, and Dr. Waters will serve as Senior Operations Advisor. Dr. Runge is formerly the Assistant Secretary of Health Affairs at the Department of Homeland Security (DHS); Dr. Waters is formerly Deputy Assistant Administrator at the Transportation Security Administration and served previously as Chief of Staff of DHS’s Office of Health Affairs and as Counselor to two DHS Deputy Secretaries. In addition to Drs. Runge and Waters, other Chertoff Group principals will provide periodic support to BioNeutral regarding product testing and evaluation; acquisitions and procurement activities across commercial and federal targets; and capital-raising strategies.

“I believe BioNeutral’s technology has the potential to be game-changing,” said Chad Sweet, Co-Founder and Managing Principal at the Chertoff Group. “Based on preliminary data from independent lab testing, we are enthusiastic about the potential to instantly sterilize surfaces, fabric and skin without any known environmental effects. We believe BioNeutral’s formulations have the potential to address several difficult problems facing the Nation, including influenza pandemics, national security threats such as anthrax, and in preventing expensive and dangerous hospital acquired infections.”

Mr. Sweet previously served as the Chief of Staff of DHS and at the CIA. In addition to his expertise in security, he worked for twelve years in finance with Goldman Sachs and Morgan Stanley. At Chertoff Group, Mr. Sweet utilizes his unique background in intelligence, homeland security, and investment banking to advise companies and private equity firms expanding within the defense, aerospace, and security industries.

Other principals at Chertoff Group include General Michael Hayden, former Director of the Central Intelligence and National Security Agencies; former Homeland Security Deputy Secretary Paul Schneider (who previously served as head of acquisitions for the National Security Agency and United States Navy); and former Undersecretaries of Homeland Security Charles Allen and Rear Admiral Jay Cohen.

BioNeutral’s relationship with Dr. Runge and Dr. Waters takes advantage of a unique skill set in homeland security and health care. Dr. Runge was DHS’s first Chief Medical Officer, where he led the reorganization of biodefense operations into a new Office of Health Affairs. Prior to DHS, he was the head of the National Highway Traffic Safety Administration, where he instituted programs that led to the first absolute declines in U.S. motor vehicle deaths in nearly a decade and the lowest highway fatality rate in history. He has also been a board certified emergency physician for 25 years. Dr. Waters joined the Chertoff Group after three and a half years at the Department of Homeland Security (DHS), where his portfolio included intelligence and operational aspects of border and transportation security; immigration and customs enforcement activities; emergency management and the United States Secret Service. Prior to government service, Dr. Waters held senior strategic, financial and operations roles in early-stage organizations and turnaround situations.

“Dr. Waters and I are excited about the opportunity to deepen our relationship with BioNeutral,” Dr. Runge said. “Over the past few months, we’ve gotten to know the company, its technology and its leadership team. We believe they are on the cutting edge of biotechnology, and we’re looking forward to helping them take the next steps in developing, licensing and providing their unique formulations for the health and welfare of people.”

ABOUT THE CHERTOFF GROUP

The Chertoff Group is a security and risk management advisory firm that counsels corporate and government clients. The firm, which is based in Washington and has offices in New York City, is led by the former U.S. Secretary of Homeland Security Michael Chertoff and assists clients with addressing threats related to terrorism, biosecurity, fraud, cyber security, border protection, and supply chain security.

HELICOS BIOSCIENCES CORPORATION (NASDAQ: HLCS)

"Up 60.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/HLCS.php

Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing (tSMS)(TM) technology allows direct measurement of billions of strands of DNA, enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and is committed to providing scientists the tools to unlock the era of genomic medicine. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800.

HLCS News:

August 20 - Ontario Institute for Cancer Research Takes Delivery of a Helicos Genetic Analysis System

Leaders in the field of cancer genomics to leverage benefits of single molecule sequencing technology

Helicos BioSciences Corporation (Nasdaq: HLCS), a life science company focused on innovative genetic analysis technologies, announced the placement of a Helicos™ Genetic Analysis System at the Ontario Institute for Cancer Research (OICR) with Drs. Tom Hudson and John McPherson.

“We are very excited to be working with such a distinguished institution on the application of our technology to the study of cancer genomics” stated Ron Lowy, Helicos Chief Executive Officer.

The Helicos Genetic Analysis System is the world’s first and only commercially available, single molecule sequencing technology, and enables scientists to conduct revolutionary studies in the fields of genome biology, cancer research, common diseases, and microbiology without DNA ligation or amplification. Genetic analysis with Helicos’s technology eliminates the biases, complexity and errors introduced by DNA amplification, requires minute amounts of starting material, and provides the most direct and accurate view of biological samples.

“The translational cancer research we are conducting at our center can benefit greatly from the advantages of single molecule sequencing” stated Tom Hudson, President and Scientific Director of the OICR. “We hope to use this technology for the unbiased and comprehensive characterization of tumor samples to ultimately lead to discoveries that have a clinical impact.”

ABOUT THE ONTARIO INSTITUTE FOR CANCER RESEARCH

The Ontario Institute for Cancer Research is a new research institute, moving Ontario to the forefront of discovery and innovation. It is dedicated to research in prevention, early detection, diagnosis and treatment of cancer. OICR is a not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation.

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Disclosure: OTCPicks.com is being compensated eight thousand dollars by a third party (Mickey Reno) for EWRC advertising and promotional services. OTCPicks.com has been compensated two thousand five hundred dollars by a third party (Blue Wave Advisors) for BONU advertising and promotional services.